(MENAFN Editorial) JACKSONVILLE, Fla., Nov. 17, 2017 /PRNewswire/ -- (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced its Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, "Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system," at the , held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
TapImmune Event Details:
Title:Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system About TapImmune Inc.
TapImmune Inc. is a leader in the TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.
To receive future press releases via email, please visit:
Follow us on Twitter , or follow us on . Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at . The Company assumes no obligation to update the forward-looking statements.
View original content with multimedia:
SOURCE TapImmune Inc.Related Links
MENAFN1711201700701241ID1096105236
